Firstly, PTK7-GEMs targeted transport reduces system consumption; Secondly, it solves the weak affinity of GEM toward BC, which results in more GEM accumulating in the tumor site; Thirdly, PTK7 might mediate more efficient pathways and reduce chemotherapeutic drug resistance; Lastly, the reduction in adverse side effects makes the body more tolerant to GEM and the long-term response rate to GEM might improve. Here, PTK7 is linked to neoplasm.